FDA Inspection
Baxter Oncology GmbHBaxter Oncology GmbH – FDA Inspection, Jun 27, 2017
Record Details
This FDA Inspection record concerns Baxter Oncology GmbH, with an inspection on June 27, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
- People
- Christina A. Capacci-Daniel (Issuing Officer)
- Dennis Cantellops Paite (Issuing Officer)
- Kumar G. Janoria (Issuing Officer)
View Company Profile
ID · 64eef675-4ce9-4232-82e4-ae06945fe393
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1019700
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
Other FDA inspections of Baxter Oncology GmbH
11| Date | Classification | Office | Project area |
|---|---|---|---|
| September 26, 2025 | OAI | Office of Inspections and Investigations | Drug Quality Assurance |
| August 27, 2024 | Not classified | Office of Inspections and Investigations | |
| May 3, 2023 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 29, 2020 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 3, 2019 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Baxter Oncology GmbH
- FDA Inspection 1283802 - 2025-09-26
- FDA Inspection 1249702 - 2024-08-27
- FDA Inspection 1206312 - 2023-05-03
- FDA Inspection 1161093 - 2020-01-29
- FDA Inspection 1106642 - 2019-09-03
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.